These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17600395)

  • 1. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
    Carter NJ; Scott LJ
    Drugs; 2007; 67(10):1513-9. PubMed ID: 17600395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemate P/Humate-P: a systematic review.
    Berntorp E
    Thromb Res; 2009 Nov; 124 Suppl 1():S11-4. PubMed ID: 19944255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
    Schramm W
    Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.
    Kouides P; Wawra-Hehenberger K; Sajan A; Mead H; Simon T
    Transfusion; 2017 Oct; 57(10):2390-2403. PubMed ID: 28691218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
    Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
    Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
    Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of immune tolerance induction with Haemate P in haemophilia A.
    Escuriola Ettingshausen C; Kreuz W
    Haemophilia; 2014 May; 20(3):333-9. PubMed ID: 24165472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease.
    Federici AB
    Expert Opin Drug Saf; 2009 Mar; 8(2):203-10. PubMed ID: 19309248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
    Gröner A
    Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
    Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.